BioMedNewsBreaks Archive - Page 194 of 215

FridayNov 13, 2020 10:31 am

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Q2 Results, Provides Update on CNS Pipeline and Business Progress

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today reported its financial results for the fiscal 2021 second quarter ended September 30, 2020. In addition, the company provided an update on its CNS pipeline and business progress. “We see a significant rise in mental health concerns as the global COVID-19 pandemic continues to impact the daily lives of millions of individuals. We are committed to developing innovative therapies that provide relief to those suffering from anxiety and depression, and we are working diligently towards that goal,” said VistaGen…

ThursdayNov 12, 2020 3:31 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Poised at Convergence of AI, Cancer Care

Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company, focuses on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. The company is set to play a key role as the integration of AI technology within cancer care continues to improve the accuracy and speed of diagnosis, aid in clinical decision-making and lead to better health outcomes. A recent article discussing growing opportunity in this sector reads, “The National Cancer Institute (‘NCI’) in the United States has separately revealed that it is increasingly looking to invest in supporting research and developing infrastructure centered around the usage of…

ThursdayNov 12, 2020 1:15 pm

BioMedNewsBreaks – CB Scientific Inc. (CBSC) Enters Definitive Agreement to Acquire Datrix LLC

CB Scientific (OTC: CBSC), engaged in providing innovative products and services for the ambulatory noninvasive cardiac monitoring space, today announced definitive purchase agreement to acquire Datrix LLC, a global ambulatory device manufacturer based in Escondido, California. Datrix brings to CBSC a diversely experienced team of highly qualified individuals with extensive knowledge of design and engineering related to medical devices utilized in this ever-expanding market. The acquisition further strengthens CBSC’s digital offering with the addition of an existing commercially available product line, which includes wireless mobile cardiac telemetry, cardiac event, extended and standard holter monitoring through the Datrix Sirona and VX3…

ThursdayNov 12, 2020 12:03 pm

BioMedNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Reports Positive Preclinical Data on PH94B’s Mechanism of Action

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced new in vitro electrophysiology data. According to the update, the data demonstrate that the mechanism of action of PH94B, the intranasal neuroactive steroid the company is preparing for Phase 3 development as a potential acute rapid-onset treatment of anxiety in adults with social anxiety disorder, does not involve direct activation of GABA-A receptors, in distinct contrast to the mechanism of action of benzodiazepines (“benzos”), which act as direct positive modulators of GABA-A receptors. “We are very pleased with…

ThursdayNov 12, 2020 11:28 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Releases Financial Results for Third Quarter

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has released its financial results for Q3 2020. In addition, the company reported on important third-quarter highlights and provided an update on key objectives. Dario ended the third quarter with cash and cash equivalents of $37 million and plans to focus on its U.S. commercial sales and marketing infrastructure with the end goal of B2B2C pipeline growth. In addition, through its agreements with Vitality Group and HMC Healthworks, the company is committed to becoming a B2B2C digital therapeutics leader. The report also noted that Eric Milledge had been appointed…

ThursdayNov 12, 2020 10:35 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Hosting Webcast for Discussion of Phase 2 Clinical Trial Design

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has scheduled a webcast today during which it will be discussing its plan to submit a phase 2 clinical trial design for FDA review. The call, which will be moderated by Robert LeBoyer, managing director of Equity Research at Ladenburg Thalmann & Co. Inc., will start at 4:30 p.m. ET. The phase 2 trial design is for the U.S. trial for CNSP’s Berubicin. Berubicin is the company’s lead drug candidate for the treatment of glioblastoma multiforme…

WednesdayNov 11, 2020 11:21 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate in Life Sciences Summit Panel

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its senior vice president of intellectual property and licensing, Thomas Gallagher, will participate at the annual NYC-based Life Sciences Summit. Gallagher will take part in a panel discussion titled, “Show Me the Money: Preparing Your Company for Funding,” at the event, slated to place virtually November 17-18, 2020. During the panel discussion, scheduled for 10-10:45 a.m. ET on Tuesday, November 17, experts will provide insight into the essential building blocks needed for emerging companies to reach their goals.…

TuesdayNov 10, 2020 2:40 pm

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Completion of Strategic Merger

180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the successful closing of its transaction with KBL Merger Corp IV. Prior to the merger’s closing, KBL Merger Corp. changed its name to 180 Life Sciences Corp., and 180 Life Sciences Corp. changed its name to 180 Life Corp., which now operates as a wholly owned subsidiary of the company. As a result of the merger, the units and rights of KBL Merger Corp. ceased trading, and the shares of its…

TuesdayNov 10, 2020 1:10 pm

BioMedNewsBreaks – Antibe Therapeutics Inc. (TSXV: ATE) (OTCQB: ATBPF) Graduates to the TSX

Antibe Therapeutics (TSXV: ATE) (OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced its receipt of final approval from the Toronto Stock Exchange (“TSX”) to list its common shares on the TSX. According to the update, Antibe’s shares will commence TSX trading under the company’s existing ticker symbol “ATE” at market open on Thursday, November 12, 2020. “We are excited to graduate to the TSX, as it represents a further step in reaching the broader investment community while increasing liquidity for our shareholders,” said Dan Legault, Antibe’s…

TuesdayNov 10, 2020 11:35 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Expands Scientific Advisory Board with Strategic Appointment

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the addition of George K. Gittes, MD to its Scientific Advisory Board (“SAB”). According to the update, Dr. Gittes is the inventor of GNPX’s licensed diabetes gene therapy technology that is currently in development and serves as the chief of pediatric surgery and surgeon-in-chief emeritus at the UPMC Children’s Hospital of Pittsburgh. “We are delighted to have Dr. Gittes join our Scientific Advisory Board as Genprex continues to advance its diabetes program,” said Rodney Varner, Genprex’s president and chief…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Q2 Results, Provides Update on CNS Pipeline and Business Progress

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Poised at Convergence of AI, Cancer Care

BioMedNewsBreaks – CB Scientific Inc. (CBSC) Enters Definitive Agreement to Acquire Datrix LLC

BioMedNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Reports Positive Preclinical Data on PH94B’s Mechanism of Action

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Releases Financial Results for Third Quarter

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Hosting Webcast for Discussion of Phase 2 Clinical Trial Design

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate in Life Sciences Summit Panel

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Completion of Strategic Merger

BioMedNewsBreaks – Antibe Therapeutics Inc. (TSXV: ATE) (OTCQB: ATBPF) Graduates to the TSX

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Expands Scientific Advisory Board with Strategic Appointment

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search